

October 22, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001

BSE Scrip Code: 500390

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

NSE Scrip Symbol: RELINFRA

Dear Sir(s),

Sub: Newspaper Publication – Special Window for transfer and dematerialisation of physical shares

Please find enclosed copies of the newspaper publication dated October 22, 2026, published in the Financial Express (English) and Navshakti (Marathi), pertaining to the notice issued to the shareholders of the Company pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/II/3750/2026 dated January 30, 2026, regarding the opening of a special window till February 04, 2027, to facilitate the transfer and dematerialisation of physical shares that were sold /purchased prior to April 01, 2019.

The above information is also available on the website of the Company at www.rinfra.com

We request you to kindly take the above information on record.

Yours faithfully,

For Reliance Infrastructure Limited

PARESH
PURUSHOT
TAMLAL
RATHOD

Paresh Rathod
Company Secretary

Encl: As above

SHRIRAM FINANCE LIMITED

PUBLIC NOTICE

This is to inform our customers and public at large that our **Vapi - II Branch** located at Shanti Complex, No. 206, Second Floor, Survey No. 134, Off NH No. 48, Vapi, Gujarat - 396191 will shift to Office No : 108, First Floor, Shanti Complex, Above Ford Show Room, Near Vapi Court, National Highway No. 8, Vapi, Gujarat - 396191 from 22nd January 2027.

The Customers are requested to contact the new office premises for their needs.

REGIONAL BUSINESS HEAD

SHRIRAM FINANCE LIMITED

PUBLIC NOTICE

This is to inform our customers and public at large that our **Bharuch Branch** located at First & Second Floor, Above Yamaha Showroom, Opposite Govardhan Hospital, Old NH 8, College Road, Bharuch, Gujarat - 392001 will shift to Office No.- B208, Second Floor, Alpha Arcades, Bharuch GIDC, Near Abc Chokdi, Bharuch, Bharuch, Gujarat - 392001 from 22nd January 2027.

The Customers are requested to contact the new office premises for their needs.

REGIONAL BUSINESS HEAD

SHRIRAM FINANCE LIMITED

PUBLIC NOTICE

This is to inform our customers and public at large that our **Guntur - II Branch** located at D No. 12-25-43, First Floor, Bosubomma Centre, Beside Santhosh Automotives, Guntur, Andhra Pradesh - 522001 will shift to House No. 12-25-168, First Floor, Shops No. 11,12,13, G.V. Doctors Plaza, Main Road, Nehru Nagar (Guntur), Guntur, Andhra Pradesh - 522001 from 22nd January 2027.

The Customers are requested to contact the new office premises for their needs.

REGIONAL BUSINESS HEAD

SAMMAAN CAPITAL LIMITED

Regd office: A - 34, 2nd & 3rd Floor, Lajpat Nagar-II, New Delhi-110024

NOTICE FOR SALE OF STRESSED FINANCIAL ASSETS

Sammaan Capital Limited, a non-banking financial company, invites Expression of Interest (EOI) along with non-disclosure agreement for sale of Stressed Financial Assets. Interested eligible investors are requested to intimate their willingness to participate in the auction by way of an "Expression of Interest".

The data room will be open from October 23, 2026 to November 28, 2026, and last day for submission of bid is November 30, 2026.

For detailed terms and conditions, please mail us at loanassignment_scl@sammaancapital.com

Mumbai, October 22, 2026

TATA POWER

(Corporate Contracts Department)

The Tata Power Company Limited, 2nd Floor, Sahar Receiving Station, Sahar Airport Road, Andheri East, Mumbai-400059

(Board Line: 022-67173917) CIN: L28920MH1919PLC000567

NOTICE INVITING TENDER (NIT)

The Tata Power Company Limited invites tenders from eligible vendors for the following packages (Two Part Bidding) in Mumbai.

A) Construction of 60 MVA transformer foundation with fire wall at Mankhurd. (Package Ref No: CC27SB033).

Interested & eligible bidders for the above package to submit Tender Fee, Authorization Letter before **15:00 Hrs. Tuesday, 27th October 2026**. For detailed NIT, please visit Tender section on website <https://www.tatapower.com>. For detailed NIT, please visit Tender section on website <https://www.tatapower.com>. Also, all future corrigendum's if any, to the said tender will be published on Tender section of above website (**Tata Power → Business Associates → Tender Documents**) only.

RELIANCE Infrastructure

Reliance Infrastructure Limited

CIN: L75100MH1929PLC001530

Regd. Office: Reliance Centre, Ground Floor, 19, Walchand Hirachand Marg, Ballard Estate, Mumbai 400 001

Tel.: +91 22 4303 1000, Website: www.rinfra.com

E-mail: rinfra.investor@reliancegroupindia.com

NOTICE TO SHAREHOLDERS

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALISATION OF PHYSICAL SHARES

Further to our newspaper advertisement dated August 22, 2026 and in terms of SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026 ('SEBI Circular'), the Shareholders are once again informed that a special window has already been opened for a period of one year from February 05, 2026 to February 04, 2027 to facilitate transfer and dematerialisation (Demat) of physical shares which were sold/purchased prior to April 01, 2019. The applicability of this window shall be as per the below matrix and subject to conditions stated in the SEBI Circular:

Lodgement for transfer before April 01, 2019	Availability of Original Share Certificate with the Shareholder	Eligibility to lodge in the current Special Window
No, it is a fresh lodgement	Yes	Yes
Yes, but was rejected/ returned/ not attended to due to deficiency in the documents	Yes	Yes
Yes, was lodged	No	No
No, was not lodged	No	No

The shares so transferred shall be mandatorily credited to the transferee's demat account and shall be under lock-in for a period of one year from the date of registration of transfer. Such shares shall not be transferred/lien-marked/pledged during the said lock-in period. Transfers of disputed shares and shares transferred to IEPF are not considered under this window.

Eligible shareholders who wish to avail this opportunity may submit the transfer request along with requisite documents to the Company's Registrar and Transfer Agent, KFin Technologies Limited (Unit: Reliance Infrastructure Limited) at their office at Selenium Tower-B, Plot No. 31 & 32, Gachibowli, Financial District, Nanakramguda, Hyderabad- 500 032.

For Further Information, shareholders may refer to the SEBI Circular available at www.sebi.gov.in or send an email to rinfra.investor@reliancegroupindia.com or einward.ris@kfintech.com.

Further, the Company encourages its Members to register or update their email IDs with the Depository Participants/ KFinTech/Company to receive all communications electronically. Members holding shares in physical form are requested to consider dematerializing their holdings to ensure compliance with SEBI guidelines and to facilitate faster and safer transactions. Further, pursuant to SEBI Master Circular No. HO/38/13(4)2026-MIRSD-POD/14298/2026 dated February 06, 2026, members, whose folios are not updated with PAN, KYC details or Choice of Nomination, are requested to update the above details by submitting the relevant ISR Forms to KFinTech by emailing to einward.ris@kfintech.com or send the physical copy at above mentioned address.

For Reliance Infrastructure Limited

Place : Mumbai

Date : October 21, 2026

Parash Rathod

Company Secretary

UTL SOLAR

FUJIYAMA POWER SYSTEMS LIMITED

(Formerly Fujiyama Power Systems Private Limited)

CIN: L31909DL2017PLC326513

Registered Office: 53A/6, Near NDPL Grid Office, Near Metro Station, Industrial Area, Sat Guru Ram Singh Marg, Delhi - 110015. E-mail id: investor@utlsolarfujiyama.com Website: www.utlsolarfujiyama.com

NOTICE OF POSTAL BALLOT AND E-VOTING INFORMATION

Notice is hereby given to the Members of **Fujiyama Power Systems Limited** ('the Company') that pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013 (the Act) read with Rules 20 and 22 of Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), Secretarial Standard - 2 ('SS-2') on General Meetings issued by the Institute of Company Secretaries of India and General Circular No. 03/2025 dated 22nd September, 2025 and in accordance with the requirements laid down in previous circulars issued by the Ministry of Corporate Affairs in this regard ('MCA Circulars') and other applicable provisions of the Act, Rules, Regulations, MCA Circulars, etc. for the time being in force, consent and approval of the Members of the Company is being sought through postal ballot process by voting through electronic means ('remote e-voting') in respect of the Special Business, i.e. "To consider and approve the raising of funds by way of Qualified Institutions Placement in one or more tranches" (Special Resolution), as set out in the Postal Ballot Notice dated October 15, 2026. The Postal Ballot Notice is available on the Company's website www.utlsolarfujiyama.com and is also available on the websites of the BSE Limited ('BSE') at www.bseindia.com and National Stock Exchange of India Limited ('NSE') at www.nseindia.com, and MUFG Intime India Private Limited ('MUFG') at <https://instavote.linkintime.co.in/>.

Pursuant to the aforesaid provisions, the Company has completed the dispatch of electronic copies of the Postal Ballot Notice along with the explanatory statement thereto on Wednesday, October 21, 2026 only through electronic mode to all those Members whose email addresses are registered with the Company or Depository Participants ('DPs') or Registrar & Share Transfer Agent ('RTA') of the Company and whose names appeared as Members in the Company's Register of Members / List of Beneficiaries as on **Cut-off date i.e. Thursday, October 15, 2026**. Physical copies of the Postal Ballot Notice along with Postal Ballot forms and pre-paid business reply envelopes are not sent to the Members for the Postal Ballot in line with the exemption provided in the aforesaid MCA Circulars.

The Company has engaged the services of MUFG Intime India Private Limited ('MUFG') to provide remote e-voting facility to its members to exercise their right to vote on the resolution proposed in the Postal Ballot Notice. The communication of the assent or dissent of the Members would take place through remote e-voting only. A member may exercise voting through remote e-voting only as per the aforesaid provisions. For casting the votes, the Members may read the instructions thereof provided in the Postal Ballot Notice carefully. Members are requested to note that remote e-voting period shall commence on Friday, October 23, 2026 at 09:00 A.M. and end on Saturday, November 21, 2026 at 05:00 P.M. (including both days), and the remote e-voting module shall be disabled for voting by MUFG immediately thereafter. Any Postal Ballot received from a Member through electronic means beyond the aforesaid date and time shall not be considered valid, and voting through electronic means shall not be permitted thereafter. Once the vote on the resolution is cast by a Member, the Member shall not be allowed to change it subsequently. The voting rights of a Member shall be in proportion to his / her / its shareholding in the paid-up share capital of the Company as on the Cut-off date i.e. Thursday, October 15, 2026.

The manner of remote e-voting by the Members holding shares in dematerialized mode, physical mode and for the Members who have not registered their email address is provided in the Postal Ballot Notice. The manner in which the persons who have forgotten the User ID and / or Password, can obtain / generate the same, has also been provided in the said Notice. Members who have not received the Postal Ballot Notice may download the same from the websites mentioned.

The Board of Directors of the Company has appointed Mr. Raghav Bansal (FCS No: 12328, COP No: 14869), Proprietor of M/s Raghav Bansal & Associates, Practising Company Secretaries, as Scrutinizer for conducting the Postal Ballot process in a fair and transparent manner. The results of the Postal Ballot shall be declared on or before Tuesday, November 24, 2026, i.e. within two working days of the conclusion of remote e-voting, and the same, along with the Scrutinizer's Report, shall be displayed on the Company's website www.utlsolarfujiyama.com and shall also be communicated to the stock exchanges and will be displayed simultaneously on the websites of the stock exchanges and MUFG.

The resolution, if approved by the requisite majority, shall be deemed to have been passed on the last date of e-voting i.e. Saturday, November 21, 2026 at 05:00 P.M. and shall be deemed to have been passed at a general meeting convened in that behalf.

Members who have not updated their e-mail address are requested to register the same, in respect of shares held by them in electronic form with the Depositories through their DPs and in respect of shares held in physical form by writing to the Company's RTA, MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083 or at E-mail: investor.helpdesk@in.mgms.mufg.com and submitting the requisite documents as may be sought by the RTA in this regard.

In case you have any queries or issues regarding remote e-voting from the MUFG e-Voting System, you can write an email to enotices@in.mgms.mufg.com or contact **Rajiv Ranjan**, Sr. Assistant Vice President - e-Voting, T: +91 22 4918 6000, MUFG Intime India Private Limited, C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083.

For Fujiyama Power Systems Limited

(Formerly Fujiyama Power Systems Private Limited)

Sd/-

Mayuri Gupta

Company Secretary & Compliance Officer

Date: October 21, 2026

Place: New Delhi

INTEGRIS MEDTECH LIMITED

(FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED)

Our Company was incorporated as 'Integrus Health Private Limited' as a private limited company under Companies Act, 1956 pursuant to certificate of incorporation dated April 25, 2008, issued by Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana at Delhi. Our Company changed its name to 'Integrus Medtech Private Limited', pursuant to which a fresh certificate of incorporation dated June 30, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. Further, our Company was converted into a public limited company pursuant to the resolution passed by our Board of Directors on July 16, 2025, and special resolution passed by our Shareholders on August 1, 2025 and the name of our Company was changed to 'Integrus Medtech Limited' and consequently, a fresh certificate of incorporation dated August 8, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. For further details in relation to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 305 of the DRHP.

Registered Office: 1st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, New Delhi, 110 060 Delhi, India

Corporate Office: 15th Floor, One Horizon Center, Golf Course Road, DLF Phase 5, Sector 43, Gurgaon 122002, Haryana, India

Tel: +91 124 4673710; Website: www.integrusmedtech.com; Contact person: Darpan Batra, Group General Counsel, Company Secretary and Compliance Officer

E-mail: investors@integrusmedtech.com; Corporate Identity Number: U85110DL2008PLC177230

NOTICE TO INVESTORS

ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED OCTOBER 9, 2025 (THE "ADDENDUM" AND SUCH DRAFT RED HERRING PROSPECTUS, THE "DRAFT RED HERRING PROSPECTUS" OR THE "DRHP")

PROMOTERS OF OUR COMPANY: EVERCURE HOLDINGS PTE. LTD., MEDICORE HOLDINGS PTE. LTD., GURMIT SINGH CHUGH AND PUNITA SHARMA

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF INTEGRIS MEDTECH LIMITED (FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED) (OUR "COMPANY" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹6,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE (THE "OFFER FOR SALE") OF UP TO 10,837,266 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EVERCURE HOLDINGS PTE. LTD., (THE "PROMOTER SELLING SHAREHOLDER" AND SUCH SHARES, THE "OFFERED SHARES").

This Addendum is in reference to the DRHP filed with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. In this regard, potential investors should note that in accordance with the SEBI ICDR Regulations and the guidance provided by SEBI pursuant to its email dated April 13, 2026 read with its email dated October 12, 2026 to the Association of Investment Bankers of India permitting issuers to increase or decrease the fresh issue size up to 50%, without re-filing the draft red herring prospectus for all initial public offerings opening on or before March 31, 2027 ("the SEBI Communication"), and pursuant to Board resolution dated October 19, 2026, our Company has decided to reduce the size of the fresh issue in the Offer from ₹9,250 million as disclosed in the DRHP to ₹6,000 million (i.e. within the permissible limit of up to 50%) due to evolving market dynamics resulting from heightened volatility arising from external geopolitical developments. Further, our Company has (i) received letters from Gurmit Singh Chugh and Punita Sharma, each dated October 18, 2026, who had earlier consented to participate as selling shareholders in the Offer for Sale, informing our Company of their decision to withdraw the offer of their portion of the Offered Shares in the Offer and (ii) consent letter dated October 19, 2026 from Evercure Holdings Pte. Ltd. informing our Company of its decision to decrease its portion of the Offered Shares in the Offer for Sale to up to 10,837,266 Equity Shares. Accordingly, the Offer size has been revised and disclosed through this Addendum. All references to the Fresh Issue size, Offer for Sale and the overall Offer size in the DRHP shall be revised and modified at all applicable places in the Red Herring Prospectus, the Abridged Prospectus, and Prospectus, as applicable.

Potential investors may note that in order to assist the investors to get a complete understanding of the updated information, the sections titled "The Offer" and "Objects of the Offer" beginning on pages 80 and 116 respectively, of the DRHP, have been appropriately updated only to reflect changes relating to the updated Fresh Issue size, Offer for Sale and the Offer size and included in this Addendum to reflect, inter alia, the above modifications.

Accordingly, the required updates and amendments to the portions of the cover page and sections titled "Definitions and Abbreviations", "The Offer", "Capital Structure", "Objects of the Offer" and "Offer Structure" beginning on pages 1, 80, 98, 116 and 571 respectively, of the DRHP, will be updated in the Red Herring Prospectus, Abridged Prospectus, and Prospectus, as applicable.

The changes conveyed by way of this Addendum are to be read in conjunction with the DRHP and, accordingly, the corresponding references in the DRHP stand updated pursuant to this Addendum. The information in this Addendum supplements and updates the information in the DRHP, as applicable, and accordingly henceforth any reference to the DRHP shall be a reference to the DRHP read with this Addendum. However, this Addendum does not purport to, nor does it, reflect all the changes that have occurred from the date of filing of the DRHP and till the date of this Addendum. Accordingly, this Addendum does not include all the changes and/or updates that will be included in the Red Herring Prospectus and/or the Abridged Prospectus and/or the Prospectus as and when filed with the Registrar of Companies, National Capital Territory of Delhi - II at Delhi ("RoC"), the SEBI and the Stock Exchanges. Please note that the information included in the DRHP will be suitably updated, including to the extent stated/ updated by way of this Addendum, as may be applicable, in the Red Herring Prospectus, the Abridged Prospectus, and the Prospectus. Investors should not rely on the DRHP or this Addendum for any investment decision, and should read the Red Herring Prospectus, as and when it is filed with the RoC, SEBI and the Stock Exchanges before making an investment decision with respect to the Offer.

Pursuant to the reduction in the Fresh Issue size, the disclosures in the "The Offer" beginning on page 80 of the DRHP, as of the date of this Addendum stands modified. The corresponding changes set out below to reflect the revised Fresh Issue and Offer for Sale size will be updated at all applicable places in the RHP, Prospectus and Abridged Prospectus, as applicable:

Offer of Equity Shares ⁽¹⁾⁽²⁾	Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million
of which	
Fresh Issue ⁽¹⁾	Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹6,000.00 million
Offer for Sale ⁽²⁾	Up to 10,837,266 Equity Shares of face value ₹1 each, aggregating up to ₹[●] million

(1) Our Board has pursuant to its resolution dated October 19, 2026 taken on record the consent of Promoter Selling Shareholder to participate in the Offer for Sale in relation to the Offered Shares. The Promoter Selling Shareholder has authorised its participation in the Offer for Sale for the Offered Shares, as set out below:

S. No.	Promoter Selling Shareholder	Number of Offered Shares ³	Aggregate proceeds from the Offered Shares	Date of board resolution/ corporate authorisation	Date of consent letter
1.	Evercure Holdings Pte. Ltd.	Up to 10,837,266 Equity Shares of face value of ₹1 each	Up to ₹[●] million	September 29, 2025	October 19, 2026

³The Promoter Selling Shareholder, has confirmed its eligibility to participate in the Offer for Sale in accordance with Regulation 8 of the SEBI ICDR Regulations. Further, the Promoter Selling Shareholder confirms that the Offered Shares will be offered for sale in the Offer in accordance with Regulation 8A of the SEBI ICDR Regulations, to the extent applicable to the Promoter Selling Shareholder. For details of authorisations for the Offer for Sale, see "Other Regulatory and Statutory Disclosures - Authority for the Offer" on page [●].

(2) Subject to valid Bids being received at or above the Offer Price, under-subscription, if any, in any category except the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company, in consultation with the Book Running Lead Managers, and the Designated Stock Exchange, subject to applicable laws. Under-subscription, if any, in the QIB Portion (excluding the Anchor Investor Portion) will not be allowed to be met with spill-over from other categories or a combination of categories.

The disclosures in the "Objects of the Offer" beginning on page 116 of the DRHP, as of the date of this Addendum stands modified as follows will be updated at all applicable places in the RHP, Prospectus and Abridged Prospectus, as applicable:

Objects of the Fresh Issue

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:

a. Our wholly-owned Subsidiaries, namely, Transluma Therapeutics Private Limited ("Transluma Therapeutics") and Transhealth Private Limited ("Transhealth"); and

b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

2. General corporate purposes.

(collectively, the "Objects", and individually, each an "Object").

Further, our Company expects to receive the benefits of listing of the Equity Shares on the Stock Exchanges, including enhancement of our Company's brand name and creation of a public market for our Equity Shares in India.

The main objects and objects incidental and ancillary to the main objects set out in the Memorandum of Association enable us: (i) to undertake our existing business activities; and (ii) to undertake the activities for which the funds are being raised by us in the Fresh Issue and are proposed to be funded from the Net Proceeds.

Net Proceeds

After deducting our Company's share of the Offer related expenses from the Gross Proceeds received pursuant to the Fresh Issue, we estimate the net proceeds to be ₹[●] million ("Net Proceeds"), as set out in the table below:

Particulars	Estimated amount
Gross Proceeds of the Fresh Issue ¹	6,000.00
(Less) Offer related expenses in relation to the Fresh Issue ²	[●]
Net Proceeds ³	[●]

¹To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC.

²For details of the expenses related to the Offer, see "Offer Expenses" on page [●].

Requirement of funds and utilization of Net Proceeds

The Net Proceeds are proposed to be utilized in accordance with the details set out in the table below:

Sr. No.	Particulars	Amount (₹ million)
1.	Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:	5,098.51
a.	Our wholly-owned Subsidiaries, namely, Transluma Therapeutics and Transhealth	938.74
b.	Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., and Research Instruments Pte. Ltd.	4,159.77
2.	General corporate purposes ⁽¹⁾⁽²⁾	[●]
	Net Proceeds	[●]

¹The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

²To be determined upon finalisation of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Proposed schedule of implementation and deployment of Net Proceeds

We propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds set forth in the table below: (in ₹ million)

Particulars	Estimated amount proposed to be utilised from Net Proceeds	Estimated schedule of deployment of Net Proceeds in Fiscal 2027
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:	5,098.51	5,098.51
a. Our wholly-owned Subsidiaries, namely, Transluma Therapeutics and Transhealth	938.74	938.74
b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., and Research Instruments Pte. Ltd.	4,159.77	4,159.77
General corporate purposes ⁽¹⁾⁽²⁾	[●]	[●]
Total ⁽³⁾	[●]	[●]

(1) The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

(2) To be finalized upon determination of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Pursuant to a resolution passed by the Board dated October 19, 2026, our Company has approved the utilisation of the Net Proceeds for the Object and the schedule of deployment and implementation, as set out above.

Means of Finance

The fund-requirements for the Objects are proposed to be met entirely from the Net Proceeds. Accordingly, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Fresh Issue as required under Regulation 7(1)(e) of the SEBI ICDR Regulations.

This Addendum which has been filed with SEBI and the Stock Exchanges and shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrusmedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Unless stated otherwise, all references to page numbers in this Addendum are to the page numbers of the DRHP. All capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meanings ascribed to them in the DRHP.

ICICI Securities

AXIS CAPITAL

CITIGROUP GLOBAL MARKETS INDIA PRIVATE LIMITED

IIFL CAPITAL

KFINTECH

ICICI Securities Limited

ICICI Venture House

Appasaheb Marathe Marg

Prabhadevi, Mumbai 400 025

Maharashtra, India

Tel: +91 22 6807 7100

Email: integrus ipo@icicisecurities.com

Website: www.icicisecurities.com

Investor Grievance ID: customercare@icicisecurities.com

Contact person: Tanya Tiwari/ Ramesh Vaswana

SEBI registration No.: INM000011179

Axis Capital Limited

1st Floor, Axis House

Pandurang Budhkar, Marg, Worli, Mumbai 400 025

Maharashtra, India

Tel: +91 22 4325 2183

E-mail: integrus ipo@axiscap.in

Website: www.axiscapital.co.in

Investor Grievance ID: complaints@axiscap.in

Contact person: Tosit Agarwal

SEBI Registration No.: INM000012029

Citigroup Global Markets India Private Limited

1202, 12th Floor, First International Financial Centre (FIFC), G-Block, Bandra Kurla Complex, Bandra East, Mumbai 400 098

Maharashtra, India

Tel: +91 22 6175 9999

E-mail: integrusmedtech ipo@citi.com

Investor Grievance ID: investors.cgmb@citi.com

Website: <https://www.citigroup.com/global/about-us/global-presence/india/disclaimer>

Contact person: Adarsh Agarwal

SEBI Registration No.: INM000010718

IIFL Capital Services Limited

(formerly known as IIFL Securities Limited)

24th Floor, One Lodha Place

Senapati Bapat Marg, Lower Parel (West) Mumbai 400 013

Maharashtra, India

Tel: +91 22 4646 4728

E-mail: integrus ipo@iiflcap.com

Investor Grievance ID: ig.ib@iiflcap.com

Website: www.iiflcapital.com

Contact person: Yogesh Malpani / Pawan Kumar Jain

SEBI Registration No.: INM000010940

KFin Technologies Limited

Selenium Tower B, Plot No. 31 and 32 Financial District, Nanakramguda Serlingampally Hyderabad - 500 032

Telangana, India

Tel: +91 406716 2222/ 18003094001

E-mail: integrus ipo@kfintech.com

Investor Grievance ID: einward.ris@kfintech.com

Website: www.kfintech.com

Contact person: Williams R

SEBI Registration No.: INF000000221

For INTEGRIS MEDTECH LIMITED

Sd/-

Darpan Batra

Group General Counsel, Company Secretary and Compliance Officer

Place: Gurugram

Date: October 19, 2026

Integrus Medtech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated October 9, 2025 with SEBI and the Stock Exchanges. The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrusmedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 34 of the DRHP and the details set out in the RHP, when filed. Potential investors should not rely on the DRHP filed with SEBI and Stock Exchanges and should rely on the RHP, for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in 'offshore transactions' as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Adfactors

